Blood test to predict risk after surgery for high-risk GIST
Part of Cancer, Digestive system clinical trials.
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 80 years old.
- Your imaging or biopsy suggests high-risk GIST, and you haven’t had any cancer treatment before surgery (no chemo, radiation, or pre-surgery surgery).
- Your organs like liver and kidneys work well enough to safely have targeted treatment and surgery.
- After surgery, the pathology confirms it is high-risk GIST (not non–high-risk).
- You can have surgery with complete removal (an “R0 resection”), and you don’t have distant metastasis.
- You understand the study and your consent can be signed by you (and your family).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This study looks at how safe laparoscopic surgery is for stomach GISTs that are 5 cm or larger. If you’re eligible and choose to participate, your team will plan and perform surgery and track safety outcomes.
This study uses a simple blood test (liquid biopsy) to look for tiny bits of tumor DNA remaining after colorectal cancer surgery. It aims to see if the test can help predict whether the cancer will come back, especially in people with stage III cancer who will receive chemotherapy.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.